§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4147795A Expired / Lapsed US ⏱️ 0.0 years remaining

Hydantoin derivatives as therapeutic agents

Assignee: Pfizer Inc
•
Filing: 1977-11-08
•
Granted: 1979-04-03
•
Expires: 1997-11-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A series of spiro-hydantoin compounds has been prepared by condensing the appropriate carbonyl ring compound, such as the corresponding 1-indanone, 1-tetralone, 4-chromanone, thiochroman-4-one, 7,8-dihydroquinolin-5(6H)-one, 6,7-dihydropyrindin-5(5H)-one, thiondane-3-one-1,1-dioxide and 4-oxoisothiochroman-2,2-dioxide, respectively, with potassium cyanide and ammonium carbonate. The resulting hydantoin derivatives are found to be useful in preventing or alleviating chronic diabetic complications. Preferred member compounds include spiro-[imidazolidine-4,1'-indan]-2,5-dione, 6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6-chloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6,7-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6,8-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6'-fluoro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione and 6',7'-dichloro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione.

Inventors

  • 👤 Reinhard Sarges

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 08:37
CPC Classifications
C; C07; C07D; C07D235/00; C07D235/02; C07C; C07C323/00; C07D311/00; C07D311/02; C07D311/04; C07D311/22; C07D487/00; C07D487/02; C07D487/10; C07D491/00; C07D491/02; C07D491/10; C07D495/00; C07D495/02; C07D495/10

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 121 words
A method of treating a diabetic host to prevent or alleviate ocular and neuritic diabetes-associated chronic complications, which comprises orally, parenterally or topically administering to said host an effective amount of a compound selected from the group consisting of those of the formulae: ##STR10## and the base salts thereof with pharmacologically acceptable cations, wherein W is --(CH 2 ) n --; X is hydrogen and X 1 is hydrogen, hydroxy, fluorine, chlorine, bromine, lower alkyl or lower alkoxy; or X and X 1 , when taken separately, are each chlorine, lower alkyl or lower alkoxy and when taken together are --OCH 2 (CH 2 ) n O--; Y is oxygen or sulfur; Z is Y or Q wherein Q is ##STR11##
Claim 2
Independent Claim 121 words
A method of treating a diabetic host to prevent or alleviate ocular and neuritic diabetes-associated chronic complications, which comprises orally, parenterally or topically administering to said host an effective amount of a compound selected from the group consisting of those of the formulae: ##STR10## and the base salts thereof with pharmacologically acceptable cations, wherein W is --(CH 2 ) n --; X is hydrogen and X 1 is hydrogen, hydroxy, fluorine, chlorine, bromine, lower alkyl or lower alkoxy; or X and X 1 , when taken separately, are each chlorine, lower alkyl or lower alkoxy and when taken together are --OCH 2 (CH 2 ) n O--; Y is oxygen or sulfur; Z is Y or Q wherein Q is ##STR11##
Claim 3
Dependent Claim 6 words
and n is zero or one.
Claim 4
Dependent Claim 6 words
and n is zero or one.
Claim 5
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 6
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6-chloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 7
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6,8-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 8
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6,7-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 9
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6'-fluoro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione.
Claim 10
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6',7'-dichloro-spiro-[imidazolidine-4,4'-thiochroman]-2,5'-dione.

References Cited (Backward Citations)

DE1135915B Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-04-02 1982-10-02 1983-04-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-04-02 1986-10-02 1987-04-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-04-02 1990-10-02 1991-04-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag